2026-10-14T02:37:08Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33995472 2026-10-01T11:12:22Z category_67904 portal_1154 item_type_7 month_year_10_2026

Congress Presentation: IMS 2026 Rapid onset of action and sustained effect of elinzanetant in women with adjuvant endocrine therapy-associated VMS: results from the OASIS-4 Phase III clinical trial Nicholas Panay (25143914) Tommaso Simoncini (47466) Christian Rudlowski (615445) Michael Gnant (514483) Jeanne Bouteaud (25143953) Christian Seitz (2722336) Lauren Wahyudi (23627263) Kaisa Laapas (17337317) Ioanna Gkioni (21842866) Fatima Cardoso (60058) Menopause Associated with Endocrine Therapy Phase III VMS Elinzanetant OASIS-4 Endocrine therapy <p dir="ltr">EZN reduced VMS frequency from 1 day following treatment initiation, with substantial reductions 3 days after start of therapy. Sleep improved within 1 week. The results are similar to data from the OASIS-1 and -2 trials in naturally or surgically postmenopausal women and support elinzanetants potential to provide rapid relief of VMS and sleep disturbances.</p> 2026-10-01T11:12:22Z Text Presentation 10.71943/bayer.figshare.33995472.v1 https://figshare.com/articles/presentation/Congress_Presentation_IMS_2026_Rapid_onset_of_action_and_sustained_effect_of_elinzanetant_in_women_with_adjuvant_endocrine_therapy-associated_VMS_results_from_the_OASIS-4_Phase_III_clinical_trial/33995472 CC BY-ND